The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 12, 2019. Its latest SEC filing is a 15-12B from Nov 22, 2019.
10-Q for Q3 FY2019, filed Nov 12, 2019
The sections below describe the company as of the FY2018 annual report.
Sells DOPTELET, an oral treatment for low platelet counts in adults with chronic liver disease scheduled for a procedure, for specialist physicians treating those patients.
10-K for FY2018, filed Mar 5, 2019We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by…View ↗
DOPTELET is designed to mimic the effects of thrombopoietin ("TPO"), in vitro and in vivo. TPO is a hormone produced in the liver and…View ↗
We commercially launched DOPTELET for the treatment of thrombocytopenia in adult patients with CLD during the second quarter of 2018. We…View ↗
Specialty pharmacies buy DOPTELET through ICS; sales are counted when the product is delivered or over time, depending on the contract.
10-K for FY2018, filed Mar 5, 2019
$10.4M
10-K for FY2018, filed Mar 5, 2019
$10.4M ↗
ICS sells DOPTELET to specialty pharmacies with agreements with Dova; patients and healthcare providers buy from those pharmacies.
10-K for FY2018, filed Mar 5, 2019The Company is currently approved to sell DOPTELET in the United States market. The product is distributed through an exclusive…View ↗
No. It lost $72.3M in .
10-K for FY2018, filed Mar 5, 2019
10-Q for Q3 FY2019, filed Nov 12, 2019
−$21.3MView ↗
8-K, filed Nov 12, 2019
Following consummation of the Offer, the remaining conditions to the Merger were satisfied or waived and, on November 12, 2019, pursuant to…View ↗
Competes with Shionogi, Bristol-Myers Squibb, Shire, Immunomedics, Protalex, and Amgen
10-K for FY2018, filed Mar 5, 2019CLD: With respect to DOPTELET for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure, our main…View ↗
Loading...
